Literature DB >> 20300057

Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational botulinum antitoxin E.

.   

Abstract

CDC announces the availability of a new heptavalent botulinum antitoxin (HBAT, Cangene Corporation) through a CDC-sponsored Food and Drug Administration (FDA) Investigational New Drug (IND) protocol. HBAT replaces a licensed bivalent botulinum antitoxin AB and an investigational monovalent botulinum antitoxin E (BAT-AB and BAT-E, Sanofi Pasteur) with expiration of these products on March 12, 2010. As of March 13, 2010, HBAT became the only botulinum antitoxin available in the United States for naturally occurring noninfant botulism.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20300057

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN： 0149-2195            Impact factor:   17.586


  34 in total

1.  Epitope characterization of sero-specific monoclonal antibody to Clostridium botulinum neurotoxin type A.

Authors:  Cindi R Corbett; Erin Ballegeer; Kelly A Weedmark; M D Elias; Fetweh H Al-Saleem; Denise M Ancharski; Lance L Simpson; Jody D Berry
Journal:  Hybridoma (Larchmt)       Date:  2011-12

2.  An alternative in vivo method to refine the mouse bioassay for botulinum toxin detection.

Authors:  Temeri D Wilder-Kofie; Carolina Lúquez; Michael Adler; Janet K Dykes; JoAnn D Coleman; Susan E Maslanka
Journal:  Comp Med       Date:  2011-06       Impact factor: 0.982

3.  A Novel Botulinum Neurotoxin, Previously Reported as Serotype H, Has a Hybrid-Like Structure With Regions of Similarity to the Structures of Serotypes A and F and Is Neutralized With Serotype A Antitoxin.

Authors:  Susan E Maslanka; Carolina Lúquez; Janet K Dykes; William H Tepp; Christina L Pier; Sabine Pellett; Brian H Raphael; Suzanne R Kalb; John R Barr; Agam Rao; Eric A Johnson
Journal:  J Infect Dis       Date:  2015-06-10       Impact factor: 5.226

4.  A Novel Rabbit Spirometry Model of Type E Botulism and Its Use for the Evaluation of Postsymptom Antitoxin Efficacy.

Authors:  Eran Diamant; Avi Pass; Osnat Rosen; Alon Ben David; Amram Torgeman; Ada Barnea; Arnon Tal; Amir Rosner; Ran Zichel
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

5.  Outbreak of Botulism After Consumption of Illicit Prison-Brewed Alcohol in a Maximum Security Prison--Arizona, 2012.

Authors:  Seema Yasmin; Laura Adams; Graham Briggs; Joli Weiss; Kris Bisgard; Shoana Anderson; Clarisse Tsang; Evan Henke; Muhammad Vasiq; Ken Komatsu
Journal:  J Correct Health Care       Date:  2015-10

Review 6.  Antibodies for biodefense.

Authors:  Jeffrey W Froude; Bradley Stiles; Thibaut Pelat; Philippe Thullier
Journal:  MAbs       Date:  2011-11-01       Impact factor: 5.857

7.  Botulism mortality in the USA, 1975-2009.

Authors:  Kelly A Jackson; Barbara E Mahon; John Copeland; Ryan P Fagan
Journal:  Botulinum J       Date:  2016-08-04

8.  Genomic sequences of six botulinum neurotoxin-producing strains representing three clostridial species illustrate the mobility and diversity of botulinum neurotoxin genes.

Authors:  Theresa J Smith; Karen K Hill; Gary Xie; Brian T Foley; Charles H D Williamson; Jeffrey T Foster; Shannon L Johnson; Olga Chertkov; Hazuki Teshima; Henry S Gibbons; Lauren A Johnsky; Mark A Karavis; Leonard A Smith
Journal:  Infect Genet Evol       Date:  2014-12-06       Impact factor: 3.342

9.  Contagious weakness in an elderly couple with neurologic emergencies.

Authors:  Cari E Matthews; Vikram K Garg; Pallabi Sanyal; Kandan Baban; Kenneth Grudko; Adam G Field
Journal:  West J Emerg Med       Date:  2011-02

10.  Safety, Tolerability, and Pharmacokinetics of NTM-1632, a Novel Mixture of Three Monoclonal Antibodies against Botulinum Toxin B.

Authors:  J T Guptill; S M Raja; V C Juel; E B Walter; M Cohen-Wolkowiez; H Hill; E Sendra; B Hauser; P Jackson; G K Swamy
Journal:  Antimicrob Agents Chemother       Date:  2021-06-17       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.